1st Patient Enrolled in Phase 1 Trial of Antibody Therapy BHV-1100

1st Patient Enrolled in Phase 1 Trial of Antibody Therapy BHV-1100

312606

1st Patient Enrolled in Phase 1 Trial of Antibody Therapy BHV-1100

Biohaven Pharmaceuticals has begun enrolling patients in its Phase 1a/1b trial testing the company’s antibody-recruiting molecule (ARM) called BHV-1100. The trial (NCT04634435) seeks to recruit 25 adults with newly diagnosed multiple myeloma who have minimal residual disease in first remission before a stem cell transplant. One patient has now been enrolled. The trial will assess the safety and effectiveness of BHV-1100 in combination with cytokine-induced memory-like natural killer (NK) cells and low-dose interleukin (IL)-2. “This…

You must be logged in to read/download the full post.